flurazepam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	1218	17617-23-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: flurazepam stauroderm flurazepam hydrochloride flurazepam HCl	A benzodiazepine derivative used mainly as a hypnotic. Molecular weight: 387.88 Formula: C21H23ClFN3O CLOGP: 4.21 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 35.91 ALOGS: -4.59 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

flurazepam
stauroderm
flurazepam hydrochloride
flurazepam HCl

A benzodiazepine derivative used mainly as a hypnotic.

Molecular weight: 387.88
Formula: C21H23ClFN3O
CLOGP: 4.21
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 35.91
ALOGS: -4.59
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	83 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	500 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.10 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.10 %	Benet LZ, Broccatelli F, Oprea TI

Showing 1 to 5 of 5 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
April 7, 1970	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	690.75	45.59	160	2180	22004	63464678
Drug abuse	408.96	45.59	137	2203	72381	63414301
Intentional self-injury	246.27	45.59	73	2267	25614	63461068
Intentional overdose	211.36	45.59	85	2255	74067	63412615
Suicide attempt	198.65	45.59	77	2263	60841	63425841
Bradyphrenia	127.68	45.59	33	2307	6947	63479735
Toxicity to various agents	110.66	45.59	83	2257	247167	63239515
Substance abuse	74.79	45.59	20	2320	4787	63481895
Somnolence	56.31	45.59	49	2291	178636	63308046
Hypokinesia	50.19	45.59	19	2321	13917	63472765

Showing 1 to 10 of 12 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	161.19	38.45	44	1185	12092	34943610
Drug abuse	145.35	38.45	70	1159	99026	34856676
Intentional self-injury	86.41	38.45	28	1201	13743	34941959
Psychomotor hyperactivity	70.38	38.45	22	1207	9600	34946102
Feelings of worthlessness	57.98	38.45	10	1219	309	34955393
Abulia	51.68	38.45	10	1219	590	34955112
Suicide attempt	46.21	38.45	24	1205	39092	34916610
Obsessive-compulsive disorder	46.06	38.45	14	1215	5550	34950152
Restless legs syndrome	40.47	38.45	14	1215	8340	34947362

Showing 1 to 9 of 9 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sopor	797.08	36.75	200	3226	32810	79708152
Drug abuse	493.58	36.75	203	3223	162488	79578474
Intentional self-injury	338.84	36.75	102	3324	32317	79708645
Suicide attempt	185.98	36.75	84	3342	82848	79658114
Intentional overdose	181.20	36.75	89	3337	105871	79635091
Bradyphrenia	157.68	36.75	44	3382	10596	79730366
Toxicity to various agents	93.46	36.75	102	3324	421438	79319524
Psychomotor hyperactivity	57.35	36.75	23	3403	16826	79724136
Substance abuse	56.29	36.75	20	3406	10506	79730456
Hypokinesia	54.60	36.75	23	3403	19037	79721925

Showing 1 to 10 of 17 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N05CD01	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35623	anticonvulsants
CHEBI has role	CHEBI:35717	hypnotics
CHEBI has role	CHEBI:91016	GABAA receptor agonists
FDA CS	M0002356	Benzodiazepines
FDA EPC	N0000175694	Benzodiazepine
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants

Showing 1 to 10 of 16 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Insomnia	indication	193462001
Suicidal thoughts	contraindication	6471006
Disorder of lung	contraindication	19829001	DOID:850
Borderline personality disorder	contraindication	20010003	DOID:10930
Alcohol intoxication	contraindication	25702006
Shock	contraindication	27942005
Depressive disorder	contraindication	35489007
Substance abuse	contraindication	66214007
Psychotic disorder	contraindication	69322001
Sleep apnea	contraindication	73430006	DOID:0050847

Showing 1 to 10 of 20 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.24	Basic
pKa2	1.92	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRG2_HUMAN GBRB2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	IC50	8.10		WOMBAT-PK	CHEMBL
Solute carrier family 22 member 2	Transporter	O15244	S22A2_HUMAN		IC50	4.22		WOMBAT-PK

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
FL7	PDB_CHEM_ID
001463	NDDF
004584	NDDF
1172-18-5	SECONDARY_CAS_RN
19403009	SNOMEDCT_US
2551	INN_ID
27928002	SNOMEDCT_US
3393	PUBCHEM_CID
387109000	SNOMEDCT_US
4017827	VANDF

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Flurazepam	HUMAN PRESCRIPTION DRUG LABEL	1	21695-363	CAPSULE	30 mg	ORAL	ANDA	19 sections
Flurazepam	HUMAN PRESCRIPTION DRUG LABEL	1	52959-236	CAPSULE	30 mg	ORAL	ANDA	19 sections
Flurazepam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4415	CAPSULE	15 mg	ORAL	ANDA	27 sections
Flurazepam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4415	CAPSULE	15 mg	ORAL	ANDA	27 sections
Flurazepam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4430	CAPSULE	30 mg	ORAL	ANDA	27 sections
Flurazepam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0378-4430	CAPSULE	30 mg	ORAL	ANDA	27 sections
Flurazepam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0092	CAPSULE	15 mg	ORAL	ANDA	14 sections
Flurazepam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0093	CAPSULE	30 mg	ORAL	ANDA	14 sections
Flurazepam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	55289-038	CAPSULE	30 mg	ORAL	ANDA	26 sections

Showing 1 to 9 of 9 entries

Previous1Next